Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on July 18, 2024. The Company is a clinical-stage biopharmaceutical firm focused on developing antiviral treatments. The report primarily serves to disclose a press release regarding clinical development updates.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a specific event rather than a periodic financial report containing audited or unaudited financial statements.
Material Changes
The material change disclosed is the issuance of a press release on July 18, 2024, detailing updates on the clinical development of the Company's CDI-988 candidate. Specifically, the update covers results from the single-ascending dose cohorts of the Phase 1 study for CDI-988, which is being investigated as a potential antiviral treatment for coronaviruses and noroviruses.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) containing management commentary on the clinical results. The text of the 8-K itself does not contain specific forward-looking guidance, risk factors, or details on contingencies beyond the reference to the clinical study results. Investors should review the attached press release for specific data points and management outlook.
Key Facts for Investor Verification
- Verify the specific clinical data and safety results for the CDI-988 single-ascending dose cohorts in the attached press release (Exhibit 99.1).
- Confirm the next planned steps for the Phase 1 study of CDI-988 following the reported cohorts.
- Review the Company's most recent 10-Q or 10-K for current cash position and burn rate, as this 8-K does not contain financial metrics.
- Monitor for any subsequent regulatory filings regarding the Phase 1 study outcomes.